INST 0603C Patients With Unresectable/Metastatic Pancreatic Cancer Treated in the UNM Cancer

The recruitment status of this study is unknown because the information has not been verified recently.

Verified March 2009 by University of New Mexico.
Recruitment status was Active, not recruiting

Sponsor:

Information provided by:

University of New Mexico

ClinicalTrials.gov Identifier:

NCT00322712

First received: May 5, 2006

Last updated: June 23, 2010

Last verified: March 2009

History of Changes

Tracking Information

First Received Date ^ICMJE

May 5, 2006

Last Updated Date

June 23, 2010

Start Date ^ICMJE

February 2006

Estimated Primary Completion Date

December 2010 (final data collection date for primary outcome measure)

Current Primary Outcome Measures ^ICMJE

Not Provided

Original Primary Outcome Measures ^ICMJE

Not Provided

Change History

Complete list of historical versions of study NCT00322712 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Not Provided

Original Secondary Outcome Measures ^ICMJE

Not Provided

Current Other Outcome Measures ^ICMJE

Not Provided

Original Other Outcome Measures ^ICMJE

Not Provided

Descriptive Information

Brief Title ^ICMJE

INST 0603C Patients With Unresectable/Metastatic Pancreatic Cancer Treated in the UNM Cancer

Official Title ^ICMJE

INST 0603C Chart Review on Patients With Unresectable/Metastatic Pancreatic Cancer Treated in the UNM Cancer

Brief Summary

Chart Review of patients with pancreatic cancer treated with combination of irinotecan, oxaliplatin and cetuximab.

Detailed Description

Chart Review to describe the clinical outcomes in patients pancreatic cancer treated with combination of irinotecan, oxaliplatin and cetuximab.

Study Type ^ICMJE

Observational

Study Design ^ICMJE

Observational Model: Cohort
Time Perspective: Retrospective

Target Follow-Up Duration

Not Provided

Biospecimen

Not Provided

Sampling Method

Probability Sample

Study Population

Patients with unresectable/metastatic pancreatic cancer treated in the UNM Cancer Research and Treatment Center.

Condition ^ICMJE

Pancreatic Cancer

Intervention ^ICMJE

Not Provided

Study Group/Cohort (s)

Not Provided

Publications *

Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Active, not recruiting

Estimated Enrollment ^ICMJE

Estimated Completion Date

February 2011

Estimated Primary Completion Date

December 2010 (final data collection date for primary outcome measure)

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Patients with unresectable/metastatic pancreatic cancer treated in the UNM Cancer Research and Treatment Center.

Exclusion Criteria:

Not specified.

Gender

Both

Ages

18 Years and older

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

United States

Administrative Information

NCT Number ^ICMJE

NCT00322712

Other Study ID Numbers ^ICMJE

INST 0603C

Has Data Monitoring Committee

Yes

Responsible Party

Fa-Chyi Lee, MD; Principal Investigator, University of New Mexico - CRTC

Study Sponsor ^ICMJE

University of New Mexico

Collaborators ^ICMJE

Not Provided

Investigators ^ICMJE

Principal Investigator:

Fa-Chyi Lee, MD

University of New Mexico

Information Provided By

University of New Mexico

Verification Date

March 2009

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top